Non-inferiority trials have become an essential instrument in clinical research, particularly when the goal is to demonstrate that an experimental treatment is not unacceptably worse than an ...

EyePoint Pharmaceuticals receives a reiterated sell rating due to ongoing clinical and commercial uncertainties despite recent progress in DME and wet AMD trials. Duravyu (EYP-1901) showed positive ...

(RTTNews) - Outlook Therapeutics, Inc. (OTLK), a biopharmaceutical company, on Thursday announced the completion of the 12-week efficacy and safety results from its NORSE EIGHT clinical trial for ...

SIS Medical AG Welcomes the Results of the VICTORY Trial Demonstrating Non-inferiority of OPN NC to Intravascular Lithotrispy (IVL) for Lesion Preparation and Stent Expansion in Severely Calcified ...

The NRG Oncology NRG-HN005 phase II/III clinical trial did not meet the non-inferiority criteria to proceed to the phase III portion of the study. The phase II portion of the NRG-HN005 evaluated two ...

The MATTERHORN trial is the first randomized trial to demonstrate the non-inferiority of TEER and surgery in patients with secondary MR. These new data may become important to guide decision making as ...

Find out more about the effectiveness of cast immobilisation versus surgery in treating unimalleolar Weber B ankle fractures.

Receive the the latest news, research, and presentations from major meetings right to your inbox. TCTMD ® is produced by the Cardiovascular Research Foundation ® (CRF). CRF ® is committed to igniting ...

SIS Medical AG, a Swiss manufacturer of the Super-High-Pressure PTCA balloon catheter (OPN NC), is pleased to announce that the results of the investigator-initiated VICTORY trial were presented ...